Capricor Therapeutics Stock (NASDAQ: CAPR)

Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Intraday Update

Markets

Movers

Trading Ideas

CAPR

CLPT

DLTR

GPCR

IIIN

QURE

VBNK

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday

The Robinhood Trade

Pre-Market Outlook

$BTC

ARHS

BASE

CDNA

GATE

HOOD

IIPR

INNV

KULR

NTHI

RGTI

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday.

Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Stock Movers

CTOR

DGLY

HLMN

ICCT

TILE

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

Health Care

Press Releases

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics to Participate in Upcoming Investor Conferences

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Earnings

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

Absci

Abivax

Akebia Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Benitec Biopharma

Celcuity

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cogent Biosciences

Immatics

Kura Oncology

MeiraGTx Hldgs

Precigen

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

Relay Therapeutics

Sage Therapeutics

Sana Biotechnology

Sionna Therapeutics

Stoke Therapeutics

Savara

Tourmaline Bio

Tyra Biosciences

Upstream Bio

Verve Therapeutics

Cantor Fitzgerald

HC Wainwright & Co.

Jones Trading

Piper Sandler

Oppenheimer

Comments

Capricor Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell